ArticleFrontiers in drug delivery2025
Mechanics-guided parametric modeling of intranasal spray devices and formulations for targeted drug delivery to the nasopharynx.
Article in Frontiers in drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Human Factors and Device Engineering in OTC Intranasal Drug Delivery: GentleMist Technology™.Pharmaceutics · 2026Review
- Article
- Decoding the mechanophysiology for inhaled onset of smallpox with model-based implications for mpox spread.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Improving the efficacy of nasal sprays by enhancing targeted drug delivery to intra-airway tissue sites prone to infection onset is hypothesized to be achievable through an optimization of key device and formulation parameters, such as the sprayed droplet sizes, the spray cone angle, and the formulation density. This study focuses on the nasopharynx, a primary locus of early viral entry, as the optimal target for intranasal drug delivery. Methods: Two full-scale three-dimensional anatomical upper airway geometries reconstructed from high-resolution computed tomography scans were used to numerically evaluate a cone injection approach, with inert particles mimicking the motion of sprayed droplets within an underlying inhaled airflow field of 15 L/min, commensurate with relaxed breathing conditions. Therein we have considered monodisperse sprayed particles sized between 10-50 Results: The resulting three-dimensional deposition contour map, obtained by interpolating the outcomes for the discrete test parameters, revealed that the mean nasopharyngeal deposition rate peaked for particle sizes Discussion: The overall findings, while implicitly tied to the two test subjects (i.e., for spray administration through four representative nasal pathways), do collectively demonstrate that rational optimization of the intranasal sprays for targeted nasopharyngeal deposition is attainable with actionable design modifications on the sprayed droplet sizes and device plume angles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.